Development of Anti-VEGF Receptor/Flk-1 Immunoliposomes for Cytotoxic Anti-Angiogenesis Therapy
Annual rept. 1 Oct 1999-30 Sep 2000
CALIFORNIA UNIV SAN FRANCISCO
Pagination or Media Count:
We hypothesized that tumor-associated endothelium can be targeted with chemotherapy-loaded immunoliposomes ILs directed against VEGF Receptor 2 VEGFR2, F1K- 1, KDR. VEGFR2 is the primary receptor for VEGF-mediated tumor angiogenesis, and as a cell surface receptor on endothelial cells provides a highly accessible target for immunoliposome therapy. Accordingly, we have developed anti-VEGFR2 ILs to deliver highly potent chemotherapeutics to VEGFR2- expressing endothelial cells for cytotoxic antiangiogenic treatment. Cloned anti-VEGFR2 scFv 4G7 sequences were expressed in E. coli, and purified scFv containing a C-terminal cysteine residue were conjugated to liposomes using three different strategies.
- Medicine and Medical Research